# Prevail Partners

Prevail Partners is an Asset Manager based in Bayport, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Bayport, United States
- **Region:** North America
- **Address:** 200 W Washington Sq, Apt 3107, Philadelphia, PA 19106, United States
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** www.prevailpartners.com
- **LinkedIn:** https://www.linkedin.com/company/prevail-partners-llc

## About

Prevail Partners is an SEC-registered investment adviser in Bayport, MN. The firm manages approximately $64 million in regulatory assets. It has 1 employee and 1 investment adviser.

## Sectors

- Digital Health
- Healthcare Services
- Enterprise Software

## People

- Mary Schaheen — President and Director
- Patrick J. Keenan — Director and Chief Strategist
- Lester Crawford — Advisory Board

## Questions

### Who runs investment decisions at Prevail Partners?

Mary Schaheen, as President and Director, leads investment decisions at the firm. She is supported by Director and Chief Strategist Patrick J. Keenan, with advisory input from former FDA Commissioner Lester Crawford. The lean decision-making structure reflects the firm's concentrated portfolio approach.

### How does Prevail Partners source proprietary deal flow?

The firm sources opportunities through deep regulatory networks, including the participation of former FDA Commissioner Lester Crawford on its advisory board. Active membership in regional industry groups like Life Sciences Pennsylvania and BioNJ further provides early visibility into emerging life sciences companies. The firm's in-house clinical trial capabilities also generate direct operational connections to early-stage biotech ventures.

### What is the relationship between Prevail Partners and Prevail InfoWorks?

Prevail InfoWorks is an affiliate company that provides clinical trial execution and management services. Portfolio companies of Prevail Partners can access these in-house services, creating an integrated model where capital investment is paired with operational support for regulatory navigation and trial management. This reduces the typical friction of outsourcing to third-party contract research organizations.

### What investment stages does Prevail Partners typically target?

Prevail Partners targets early-stage and growth-stage companies, focusing on life sciences and technology sectors. The stage coverage spans from preclinical biotech companies requiring clinical trial support to growth-stage digital health platforms scaling their regulatory and commercial infrastructure.

### What is Prevail Partners' known posture on co-investments alongside external parties?

The firm's co-investment posture has not been publicly detailed in available records. Given its lean team and integrated service model, the firm has historically maintained a concentrated, direct-investment approach rather than widely syndicating deals. Its affiliate Prevail InfoWorks serves as the primary operational co-investor in the sense that it provides services alongside capital, though this is a related-party rather than a third-party arrangement.

## Related profiles

- [Prevail Innovative Wealth Advisors](https://altss.com/profile/prevail-innovative-wealth-advisors)
- [PREVBEP](https://altss.com/profile/prevbep)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/prevail-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology